
Contributor: Physician-Health Plan Collaboration Is Key to Early Identification of Chronic Kidney Disease
By predicting which individuals are most likely to require therapies for chronic kidney disease within the next year, health plans can better organize resource allocation to smooth or delay the transition for the patient, according to Rehan Waheed, MD of Quest Diagnostics.
By the
Yet, 1
CKD and end-stage renal disease (ESRD) are massive expenditures, with most resources focusing on treatment after damage has already been done. Underscoring this, patients with ESRD qualify for coverage under
Taking steps to improve an at-risk patient’s health before drastic measures like dialysis or transplant are necessary is important in providing the best care. While this may lead to a higher upfront investment, over time, prioritizing these prevention-focused strategies will ultimately create cost savings as conditions like ESRD, and others that may come as a complication of CKD, are limited. The question is, what should the medical community do differently to close gaps in screening to diagnose more patients in the early and more easily treatable stages of CKD?
First, utilizing population management tools to help identify patients early on can allow for intervention in the beginning stages of disease progression, helping to close gaps in care. Based on historical data, new at-risk members can be found and receive intervention like referrals, additional testing, and case management earlier. Collaborating with health plans to find hidden disease and risk-stratify patient populations can also be beneficial, and allows for providers and partners to leverage data and analytics to identify the patients at highest-risk for CKD for both early patient outreach and to arm physicians with vital educational content. In this way, health plans can take a proactive approach to determine the risk of new patients, rather than waiting for the next claim, which could delay care by many months.
For those patients that will need renal replacement therapies, or dialysis, certain tools can help predict timing to allow for peritoneal, instead of catheter, dialysis starts and lead time for transplant consideration. By predicting which individuals are most likely to require these therapies as soon as in the next 12 months, health plans can better organize resource allocation to smooth or delay the transition for the patient. Utilizing these tools can ultimately lead to better quality of life for each patient, and a possible reduction in the costs of care. Additionally, we cannot undercut the importance of meeting patients where they are using low-friction, patient engagement programs to help patients understand and manage their CKD risk, as well as provide education and guidance in making lifestyle modifications to limit CKD progression.
Taking a prevention-focused approach with at-risk patients, including those with diabetes and high blood pressure, is the best tool we have to deliver better care. However, the progression of the COVID-19 pandemic has made ensuring individuals receive the care they need challenging. Many patients are only now getting back to care after delaying in-person medical visits for fear of COVID-19 contagion. We have seen the effects these delayed appointments can cause: cancer diagnoses
Physicians and health plans can and should work together on this important issue. Access to screenings and educational tools can drastically improve outcomes for the patients most in need of intervention. Lack of adherence to guidelines can cause longstanding effects for patient populations, so it is critical that physicians take advantage of the tools at their disposal to ensure these tests are utilized as recommended.
Dr. Waheed joined Quest Diagnostics as Senior Medical Director and Chief Medical Informatics Officer in 2021. In his leadership role at the critical intersection of medicine, informatics, and business, he oversees clinical expertise for Quest’s healthcare analytics solutions while also championing important initiatives to advance analytics in public health. Dr. Waheed is a proponent of value-based, patient-centered healthcare leveraging health information technology, and is board-certified in Internal Medicine.
Reference
- Chronic kidney disease in the United States, 2021. CDC. Updated March 4, 2021. Accessed May 17, 2022.
https://www.cdc.gov/kidneydisease/publications-resources/ckd-national-facts.html - Quick reference guide on kidney disease screening. National Kidney Foundation. Accessed May 17, 2022.
https://www.kidney.org/kidneydisease/siemens_hcp_quickreference#:~:text=Therefore%2C%20it%20is%20recommended%20that,in%20a%20spot%20urine%20sample - Folkerts K, Petruski-Ivleva N, Comerford E, et al. (2021). Adherence to chronic kidney disease screening guidelines among patients with type 2 diabetes in a US administrative claims database. Mayo Clin Proc. 2021;96(4):975-986. doi:10.1016/j.mayocp.2020.07.037
- Chronic kidney disease in focus: Gaps in CKD diagnosis and care. Medpage Today. January 14, 2020. Accessed May 17, 2022.
https://www.medpagetoday.com/resource-centers/chronic-kidney-disease-focus/gaps-ckd-diagnosis-and-care/2742 - Molnar AO, Hiremath S, Brown PA, et al. Risk factors for unplanned and crash dialysis starts: a protocol for a systematic review and meta-analysis. Syst Rev. 2016;5:117. doi:10.1186/s13643-016-0297-2
- Chronic kidney disease basics. CDC. Updated February 22, 2022. Accessed May 17, 2022.
https://www.cdc.gov/kidneydisease/basics.html#:~:text=In%20the%20United%20States%2C%20diabetes,cost%20an%20additional%20%2437.3%20billion . - End-stage renal disease (ESRD). CMS. Updated December 1, 2021. Accessed May 17, 2022.
https://www.cms.gov/Medicare/Coordination-of-Benefits-and-Recovery/Coordination-of-Benefits-and-Recovery-Overview/End-Stage-Renal-Disease-ESRD/ESRD - Kaufman HW, Chen Z, Niles JK, et al. Changes in newly identified cancer among US patients from before COVID-19 through the first full year of the pandemic. JAMA Netw Open. 2021;4(8):e2125681. doi:10.1001/jamanetworkopen.2021.25681
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.